Eric Bleickardt
- Hematology top 0.1%
- Chronic Myeloid Leukemia Treatments 22
- Multiple Myeloma Research and Treatments 12
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 25
- Rheumatology top 0.5%
- Eosinophilic Disorders and Syndromes 16
- Oncology top 5%
- Peptidase Inhibition and Analysis 5
- CAR-T cell therapy research 4
-
- Cancer therapeutics and mechanisms 5
- Protein Degradation and Inhibitors 5
- Co-authors
- Hagop M. KantarjianNeil P. ShahJörge E. CortesCharles L. SawyersClaude NicaiseJohn NicollAndreas HochhausTai‐Tsang Chen
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Eric Bleickardt
39 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Hematology 3.3k
- Genetics 2.4k
- Rheumatology 1.6k
- Oncology 967
- Pathology and Forensic Medicine 256
Countries citing papers authored by Eric Bleickardt
This map shows the geographic impact of Eric Bleickardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Bleickardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Bleickardt more than expected).
Fields of papers citing papers by Eric Bleickardt
This network shows the impact of papers produced by Eric Bleickardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Bleickardt. The network helps show where Eric Bleickardt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eric Bleickardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2019 | 62 | |
| 4 | 2019 | 11 | |
| 5 | 2016 | 6 | |
| 6 | 2016 | 39 | |
| 7 | 2016 | 186 | |
| 8 | 2015 | 129 | |
| 9 | 2015 | 18 | |
| 10 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemiabreakdown → | 2010 | 1103 |
| 11 | 2009 | 29 | |
| 12 | 2009 | 48 | |
| 13 | 2009 | 5 | |
| 14 | 2009 | 167 | |
| 15 | 2008 | 181 | |
| 16 | 2007 | 20 | |
| 17 | Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemiasbreakdown → | 2006 | 1288 |
| 18 | 2006 | 8 | |
| 19 | 2006 | 10 | |
| 20 | 2002 | 19 |
About Eric Bleickardt
Eric Bleickardt is a scholar working on Hematology, Genetics, Rheumatology, Oncology and Immunology, having authored 40 papers that have together received 4.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (22 papers), Eosinophilic Disorders and Syndromes (16 papers), Multiple Myeloma Research and Treatments (12 papers), Cancer therapeutics and mechanisms (5 papers), Peptidase Inhibition and Analysis (5 papers), Protein Degradation and Inhibitors (5 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Hematology (3.3k citations), Genetics (2.4k citations), Rheumatology (1.6k citations), Oncology (967 citations) and Pathology and Forensic Medicine (256 citations). Eric Bleickardt has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Charles L. Sawyers, Claude Nicaise, John Nicoll, Andreas Hochhaus, Tai‐Tsang Chen, Moshe Talpaz and Nicholas J. Donato. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, New England Journal of Medicine and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.